MannKind Announces Key Addition to Its Executive Management Ranks
January 04 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD)
(TASE:MNKD) today announced that Stuart A. Tross, Ph.D., has
joined the company as its Chief People Officer, with
responsibilities for Human Resources, Information Technology and
West Coast Facilities. Dr. Tross will be integral in
accelerating the company's development into a world-class, global
biopharmaceutical company centered on the value of its human
capital. He will be reporting to Matthew Pfeffer, Chief
Executive Officer, and will serve on MannKind’s executive
leadership team.
Dr. Tross joins MannKind with several decades of
leadership experience in the life sciences industry. From 2006 to
2016 he served in roles of increasing responsibility at Amgen, the
last three years as Senior Vice President and Chief Human Resources
Officer responsible for Human Resources and Security on a global
basis. From 1998 to 2006 he served in a series of leadership roles
at Bristol-Myers Squibb, the last three years as Vice President and
Global Head of Human Resources for Mead Johnson Company. Stuart
received a B.S. degree from Cornell University and M.S. and Ph.D.
degrees in Industrial-Organization Psychology from the Georgia
Institute of Technology.
“To welcome Stuart to our executive management
team, with his extensive biopharmaceutical background, is both
timely and opportunistic. The addition of his wide-ranging
experience will be transformational at MannKind,” said Mr. Pfeffer.
“Stuart’s experience will not only facilitate a quick and efficient
expansion of our Afrezza launch capability, but he will be
instrumental in building an organization to accommodate other
strategic initiatives, such as product development and global
expansion.”
Dr. Tross commented, “I am excited to join the
MannKind team during this time of rapid transformation. Afrezza is
an innovative product in an area of unmet patient need with
significant growth potential, and there are a number of additional
growth opportunities in the pipeline. I look forward to
contributing to MannKind's future."
About MannKind CorporationMannKind
Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery
and development of therapeutic products for patients with diseases
such as diabetes. MannKind maintains a website at
http://www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
Forward-Looking Statements This
press release contains forward-looking statements that involve
risks and uncertainties, including statements regarding the
commercial potential of Afrezza. Words such as “believes”,
“anticipates”, “plans”, “expects”, “intend”, “will”, “goal",
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
are based upon MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
ability to generate significant product sales for MannKind,
difficulties or delays in obtaining regulatory feedback or
completing and analyzing the results of clinical studies,
MannKind’s ability to manage its existing cash resources or raise
additional cash resources, stock price volatility and other risks
detailed in MannKind’s filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2015 and periodic reports on Form 10-Q and Form
8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified
in their entirety by this cautionary statement, and MannKind
undertakes no obligation to revise or update any forward-looking
statements to reflect events or circumstances after the date of
this press release.
Company Contact:
Rose Alinaya
SVP Finance
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024